

**IPOs**

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Company Name	Last Financing Date	HQ Location	Description	Last Financing Size (Millions)	Lead Manager
Allena Pharmaceuticals (ALNA)	2-Nov-17	Newton, MA	Developer of non-systemic protein therapeutics designed to treat metabolic diseases.	74.67	Cowen and Company, Credit Suisse Securities, Jefferies
Spero Therapeutics (SPRO)	2-Nov-17	Cambridge, MA	Developer of novel therapies for the treatment of bacterial infections.	77.00	BofA Merrill Lynch, Cowen and Company, Stifel Nicolaus & Company
TissueGene (950160)	6-Nov-17	Rockville, MD	Developer of therapeutic solutions reducing pain and improving function associated with various orthopedic diseases and degenerative disorders.	183.47	NH Investment & Securities
InflaRx (IFRX)	8-Nov-17	Jena, Germany	Developer of therapeutics in the field of acute and chronic inflammation designed to prevent organ dysfunction or limit progression into organ failure.	100.01	BMO Capital Markets
Apellis (APLS)	9-Nov-17	Crestwood, KY	Developer of novel therapeutic compounds designed to treat autoimmune diseases through the inhibition of the complement system.	150.00	Citigroup Global Markets, Evercore Group, J.P. Morgan Securities
Onconova Therapeutics (ONTX)	10-Nov-17	Newtown, PA	Developer of small molecule drug candidates to treat cancer with a primary focus on myelodysplastic syndromes.	1.38	Citigroup Global Markets, Leerink Swann
Genprex (GNPX)	14-Nov-17	Austin, TX	Developer of a pan-kinase inhibitor that works to induce apoptosis in cancer cells and control cell signaling and inflammatory pathways to treat cancer for patients with late stage non-small cell lung cancer at the molecular level without harming normal cells.	22.50	Network 1 Financial Securities
Telix Pharmaceuticals (TLX)	15-Nov-17	North Melbourne, Australia	Developer of radiopharmaceutical diagnostic and therapeutic products created for the treatment of prostate cancer, renal cancer, and glioblastoma.	38.17	Taylor Collison, Wilsons Corporate Finance
Arsanis (ASNS)	16-Nov-17	Waltham, MA	Developer of monoclonal antibodies designed to prevent and treat serious infectious diseases.	60.00	Citigroup Global Markets, Cowen and Company, Piper Jaffray & Co.

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**IPOs**

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Company Name	Last Financing Date	HQ Location	Description	Last Financing Size (Millions)	Lead Manager
Orphazyme (ORPHA)	16-Nov-17	Copenhagen, Denmark	Developer of therapeutics for the treatment of lysosomal storage diseases.	94.58	Carnegie, Danske Bank
ScPharmaceuticals (SCPH)	17-Nov-17	Burlington, MA	Developer of a portfolio of transformative pharmaceutical products for subcutaneous delivery that serves as a platform for a pipeline of proven drugs and treatment model that is independent of a clinical setting.	89.60	BMO Capital Markets, Jefferies, Leerink Partners
IRRAS (IRRAS)	22-Nov-17	Stockholm, Sweden	Manufacturer and marketer of neurosurgical products.	34.60	Undisclosed

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Full Genomes Corporation	1-Nov-17	Rockville, MD	Angel	Developer of a sequencing technology designed to provide family history information and access to an extensive database of next generation sequencing reports.	0.10	Undisclosed Investors
Group K Diagnostics	1-Nov-17	Philadelphia, PA	Seed Round	Developer of a low-cost, 20 minute point-of-care diagnostic solution that leverages paper or wax-based micro-fluidics technology to reduce cost and time of testing.	Undisclosed	BioAdvance, University of Pennsylvania Endowment
Hims	1-Nov-17	San Francisco, CA	Early Stage VC	Provider of hair loss prevention medicines for males.	7.00	Cherubic Ventures, Derris, Forerunner Ventures, Harry's Razor Company, M/C Partners, Maverick Capital, SV Angel, Thrive Capital
MedtoMarket	1-Nov-17	Austin, TX	Angel	Provider of bioskills training and cadaver labs intended to validate ideas, methods, products, or concepts that will increase return on investment and handle the clinical aspects of a potential medical investment while allowing the investor to focus on the financial and managerial elements.	0.10	Undisclosed Investors
MicroBiome Therapeutics	1-Nov-17	New Orleans, LA	Angel	Developer of microbiome modulators intended for metabolic diseases that aim to improve health status by altering microbial populations and their environment in the GI tract.	1.00	Lagniappe Angels, NO/LA Angel Network, Zehnder Communications, Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Perlara	1-Nov-17	San Francisco, CA	Early Stage VC	Provider of a platform engaged in the discovery of personalized treatments for rare genetic diseases.	7.40	Al Hamra Group, Haystack Fund, Homebrew Ventures, Novartis Venture Fund, Pivotal Capital Alpha, Radical Investments, SAFE, Slow Ventures, Y Combinator
Sift Medical Data	1-Nov-17	Milwaukee, WI	Seed Round	Developer of a revenue cycle management platform that employs artificial intelligence, proprietary text mining technology, and machine learning on claims denials and patient behaviors.	0.67	Jefferson DeAngelis, Winnebago Seed Fund
Symbiotix Biotherapies	1-Nov-17	Boston, MA	Early Stage VC	Developer of a novel class of molecular therapeutics for the treatment of serious immune-mediated diseases.	5.00	Kairos Ventures
Aquaro Histology	2-Nov-17	Ann Arbor, MI	Early Stage VC	Developer of a pacesetter designed to provide automatic placement of tissue sections, reduce variation and cross-contamination, and control microtomes.	9.81	Telegraph Hill Partners, Undisclosed Investors
Golden Leaf Holdings (GLH)	2-Nov-17	Portland, OR	PIPE	Producer and distributor of medical cannabis and cannabis extracts.	29.40	Undisclosed Investors
Klotho Therapeutics	2-Nov-17	San Diego, CA	Early Stage VC	Developer of natural human protein created to delay diseases of aging: loss of cognition and kidney function, diabetes, and cancer.	10.00	Thynk Capital, Undisclosed Investors
Orchidia Pharmaceuticals	2-Nov-17	Cairo, Egypt	PE Growth/Expansion	Developer and manufacturer of ophthalmic pharmaceutical products.	Undisclosed	Lorax Capital Partners

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Ranger Health	2-Nov-17	San Antonio, TX	Early Stage VC	Provider of a mobile platform that offers a database and analyzes clinical performance, patient-reported outcomes, and service measures of local physicians and hospitals to objectively identify top-performers.	10.00	Holt Ventures
Reliq Health Technologies (RHT)	2-Nov-17	Vancouver, Canada	PIPE	Developer of mobile healthcare software that integrates wearables, sensors, voice technology, and intuitive mobile apps and desktop user interfaces for patients, clinicians, and healthcare administrators.	3.92	Undisclosed Investors
Topas Therapeutics	2-Nov-17	Hamburg, Germany	Early Stage VC	Developer of a nanoparticle-based technology designed to target autoimmune and inflammatory diseases via the induction of antigen specific immune tolerance in the liver.	21.12	Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv
Annoroad	3-Nov-17	Beijing, China	Later Stage VC	Provider of genomic research services intended to be used for clinical testing and life science research.	105.00	Ping An Ventures, SAIF Partners, SB China Venture Capital, Shenzhen GTJA Investment Group, Undisclosed Investors
Coerative	3-Nov-17	Roanoke, VA	Angel	Operator of a biotechnology company intended to develop curative strategies for the management of cardiovascular diseases related to cellular hypoxia.	0.10	Undisclosed Investors
Emerald Leaf Organics	3-Nov-17	Wellesley, MA	Angel	Provider of cannabis cultivation services intended to produce and deliver marijuana-based products for medicinal purposes.	0.09	Undisclosed Investors
Hemex Health	3-Nov-17	Portland, OR	Angel	Developer of a portable diagnostic device for diagnosing malaria and sickle cell diseases.	0.60	Elevate Capital, The Indus Entrepreneurs, The Mumbai Angels

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Innovative Surgical Designs	3-Nov-17	Bloomington, IN	Angel	Manufacturer of a spinal fixation system that provides all instruments and implants needed for thoracolumbar fixation in a compact, sterile kit.	0.50	Undisclosed Investors
Longeveron	3-Nov-17	Miami, FL	Angel	Developer of biological systems for aging and aging-associated diseases.	0.30	Undisclosed Investors
MR3 Health	3-Nov-17	San Antonio, TX	Angel	Developer of a disease prevention technology designed to treat diabetes at a lower cost.	0.10	Undisclosed Investors
Prognos	3-Nov-17	New York, NY	Later Stage VC	Developer of a health monitoring platform that provides data analytics services and laboratory tests, and also measures and tracks patient health information.	20.50	Cigna, GIS Strategic Ventures, Hermed Alpha Industrial, Hikma Ventures, Maywic Select Investments, Merck Global Health Innovation Fund, Safeguard Scientifics, Undisclosed Investors
Twine Health	3-Nov-17	Cambridge, MA	Early Stage VC	Developer of an online health activation platform designed to empower patients and care teams to collaborate.	1.50	Khosla Ventures, Provenance Venture Forum, Qiming Venture Partners, Raptor Group, Silicon Straits, Tower Capital Partners, Neoteny Labs
Alodokter	6-Nov-17	Jakarta, Indonesia	Early Stage VC	Provider of a healthcare information platform.	7.00	SoftBank Group, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
AmideBio	6-Nov-17	Louisville, CO	Angel	Provider of a biotechnology platform intended to deliver difficult-to-manufacture peptides cost effectively.	0.76	Undisclosed Investors
Counsyl	6-Nov-17	South San Francisco, CA	Later Stage VC	Provider of a genomics and DNA screening technology platform.	80.00	Perceptive Advisors, SharesPost
Exicure	6-Nov-17	Skokie, IL	Later Stage VC	Developer of immunomodulatory and gene silencing drugs for the treatment of inflammatory disorders.	31.50	AbbVie Ventures, Craig Mundie, David Walt, Eager Info Investments, Eric Lefkofsky, Knoll Capital Management, Luye Pharma Group, Mark Tompkins, Patrick Ryan, Purple Arch Ventures, The Yard Ventures, William Gates, Undisclosed Investors
New View Surgical	6-Nov-17	Boston, MA	Early Stage VC	Developer of imaging technology designed for laparoscopic surgical procedures that combines four surgical devices into one, providing the surgeon control over both visualization and instrumentation.	1.09	Keiretsu Forum, Undisclosed Investors
Nouscom	6-Nov-17	Basel, Switzerland	Early Stage VC	Developer of next generation immunotherapies created to combat cancer by activating cancer-specific T-cells.	49.28	5AM Ventures, Abingworth Management, Life Sciences Partners, Versant Venture Management

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
SharkDreams	6-Nov-17	Raleigh, NC	Angel	Developer of a digital healthcare device utilizing software and hardware technology with cloud-based data analytics and artificial intelligence capabilities that helps monitor, motivate patients, and maintain compliance while sharing the progress with doctors.	1.00	Undisclosed Investors
SynVaccine	6-Nov-17	Tel Aviv, Israel	Early Stage VC	Operator of a synthetic biology space company developing cancer immune-therapy and vaccines.	0.48	Pix Vine Capital, RAD BioMed Accelerator
AnchorDx	7-Nov-17	Guangzhou, China	Early Stage VC	Developer of next-generation sequencing techniques that utilize molecular liquid biopsies and provide non-invasive access to genetic information.	28.00	5 Dimensions Capital, ARCH Venture Partners, KingMed Diagnostics, Marathon Venture Partners, Sijia Jianxin Fund, WuXi AppTec
EOC Pharma Group	7-Nov-17	Shanghai, China	Early Stage VC	Operator of a biopharmaceutical firm intended to focus on in-licensing of global oncology products and developing, manufacturing and commercializing them in China.	32.00	H&Q Asia Pacific, Sequoia Capital China, Taikang Industry Development Fund
Hoth Therapeutics	7-Nov-17	New York, NY	Angel	Developer of therapeutics for patients suffering from atopic dermatitis, such as eczema.	1.68	Undisclosed Investors
Mindset Medical	7-Nov-17	Scottsdale, AZ	Angel	Developer of a cloud-based universal patient engagement platform designed to equip patients and physicians with relevant, updated, and secure health information.	0.35	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape



**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Progenity	7-Nov-17	San Diego, CA	Early Stage VC	Provider of molecular diagnostics services for genetic carrier screening and prenatal diagnostic services intended to offer specialized testing services for women and children.	125.00	Athyrium Capital Management
Reiley Pharmaceuticals	7-Nov-17	San Francisco, CA	Angel	Developer of biopharmaceutical products for pain, cancer and infectious diseases.	1.20	Undisclosed Investors
Tear Film Innovations	7-Nov-17	San Diego, CA	Early Stage VC	Developer of an investigational device for the treatment of evaporative dry eye and related syndromes, including meibomian gland dysfunction and blepharitis.	9.00	BrilliMedical, Tigris Ventures, Visionary Venture Fund, Undisclosed Investors
Visitpay	7-Nov-17	Boise, ID	Early Stage VC	Developer of a cloud-based healthcare financial technology platform allowing patients to easily manage, pay, and finance their healthcare bills online.	7.50	Ascension Ventures, Flare Capital Partners, Norwest Venture Partners, Undisclosed Investors
Arqule (ARQL)	8-Nov-17	Burlington, MA	PIPE	Developer of innovative cancer therapeutics directed towards molecular targets that play critical roles in the development of human cancers.	9.50	Pontifax Venture Capital
Exonics Therapeutics	8-Nov-17	Cambridge, MA	Early Stage VC	Developer of a gene editing treatment created to find a cure for Duchenne muscular dystrophy.	40.00	The Column Group
Fortuna Fix	8-Nov-17	Laval, Canada	Early Stage VC	Developer of cell reprogramming and regenerative technologies for the treatment of neurodegenerative diseases and neurotrauma.	25.00	Amgen Ventures, Macnguyen Family Office, Salamander Invest, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Horama	8-Nov-17	Paris, France	Early Stage VC	Developer of gene therapies intended to treat rare retinal diseases.	22.29	Fund+, GO Capital, IdInvest Partners, Kurma Partners, Omnes Capital, Pontifax Venture Capital, Sham Innovation Santé, Turenne Capital Partenaires
Intervention Insights	8-Nov-17	Waltham, MA	Later Stage VC	Provider of cancer therapeutic information services intended to assist community oncologists.	4.16	Beringea, Chrysalis Ventures, Undisclosed Investors
Monitored Therapeutics	8-Nov-17	Dublin, OH	Angel	Developer of a remote patient management technology designed to provide treatment of respiratory diseases in the home.	0.11	Undisclosed Investors
Pala.linq	8-Nov-17	Seattle, WA	Early Stage VC	Developer of a rehabilitation progress tracking application and comprehensive data dashboard.	2.40	Frederic Luddy, Tiny Capital, Undisclosed Investors
Phreesia	8-Nov-17	New York, NY	Later Stage VC	Provider of a SaaS patient intake management platform that manages patient information and payments, tracks patient check-in progress, and views real-time eligibility and deductible information.	17.00	Undisclosed Investors
Qurgen	8-Nov-17	Detroit, MI	Angel	Owner and operator of a biotechnology company that specializes in early stage stem cell development for research and clinical applications, including oncology and cardiovascular disease curing.	2.00	Undisclosed Investors
Rightway Healthcare	8-Nov-17	Miami, FL	Seed Round	Developer of a patient navigation and analytics platform intended to optimize healthcare expenditure for employers and employees.	2.00	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Welkin Health	8-Nov-17	San Francisco, CA	Early Stage VC	Developer of a therapeutic platform designed to empower healthcare organizations to run disease management programs for patients with mental illness, chronic diseases and pain, heart failure, addiction, hypertension, cognitive decline, and others, through engagement, education, and support programs.	8.00	Thrive Capital, Undisclosed Investors
Allegra Orthopaedics (AMT)	9-Nov-17	Lane Cove West, Australia	PIPE	Manufacturer of prosthetic implant products.	2.29	Undisclosed Investors
Alliqua (ALQA)	9-Nov-17	Yardley, PA	PIPE	Develop of an extracorporeal cell-based bio-artificial liver system.	113.00	Undisclosed Investors
Cannalysis	9-Nov-17	Costa Mesa, CA	Seed Round	Provider of laboratory testing services for medical and recreational cannabis products.	1.00	Casa Verde Capital, Undisclosed Investors
GeneNews (GEN)	9-Nov-17	Markham, Canada	PE Growth/Expansion	Developer and provider of molecular diagnostic screening services that enable the identification of a patient's individual cancer risk through convenient blood-based tests.	10.00	Milost Global
MicroBioSensor	9-Nov-17	Manchester, United Kingdom	Early Stage VC	Developer of disposable point-of-care medical devices designed for the early diagnosis of microbial infection.	0.92	Catapult Ventures, Maven Capital Partners
Nanomix	9-Nov-17	Emeryville, CA	Later Stage VC	Provider of mobile diagnostic tests that perform multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.	9.00	Gruener Ventures, Future King, Undisclosed Investors
Natural Cycles	9-Nov-17	Stockholm, Sweden	Early Stage VC	Provider of an algorithm-based fertility tracking application designed to empower women to plan their pregnancy with natural contraception.	30.00	Bonnier Growth Media, e.ventures, EQT Ventures, Sunstone Capital

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Soluble Systems	9-Nov-17	Newport News, VA	Later Stage VC	Developer of a biologic and synthetic dressing product for people with chronic wounds.	19.00	Undisclosed Investors
TurnCare	9-Nov-17	Palo Alto, CA	Early Stage VC	Manufacturer of a medical device based on a perfusion enhancement system that identifies the cause of pressure injuries, accelerates pressure injury healing times, and reduces facility-acquired pressure injury rates.	3.36	White Owl Capital Partners, Undisclosed Investors
Y Prime	9-Nov-17	Malvern, PA	PE Growth/Expansion	Developer of SaaS-based tools to facilitate clinical trials and help sponsors to bring together fragmented clinical research data into contextual information they can act on.	2.07	Undisclosed Investors
CuePath Innovation	10-Nov-17	Vancouver, Canada	Seed Round	Provider of a medication monitoring platform that connects senior citizens with care professionals and healthcare organizations through smart disposable medication packaging.	1.80	Canada Innovation Acceleration Investment, E-Fund, Genome British Columbia, Jennifer Thompson, Kirk Moir, Undisclosed Investors
GlyCardial Diagnostics	10-Nov-17	Barcelona, Spain	Early Stage VC	Developer of biomarkers to detect ischemic attack.	2.82	Caixa Capital Risc, Healthequity, Undisclosed Investors
Nativis	10-Nov-17	Seattle, WA	Angel	Developer of a non-invasive and non-thermal medical device for the treatment of solid tumors.	35.53	Undisclosed Investors
AES Compassionate Care	13-Nov-17	Chicago, IL	Angel	Owner and operator of a medical marijuana company.	3.48	David Todd Brown, Marc Gordon, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Acuitybio	13-Nov-17	Newton, MA	Angel	Developer of bio-compatible and biodegradable drug-eluting surgical products intended to commercialize novel polymer drug delivery technologies.	2.45	Undisclosed Investors
Akouos	13-Nov-17	Brookline, MA	Seed Round	Developer of targeted therapies and delivery systems to restore and preserve hearing in genetically-defined patient populations.	7.58	Enterprise Associates, Partners HealthCare Innovation
Ambra Health	13-Nov-17	New York, NY	Later Stage VC	Provider of a cloud-based medical imaging platform deigned to help in medical image management and exchange.	7.40	Canaan Partners, CHL Medical Partners, Mayo Clinic Ventures, Undisclosed Investors
Arcus Biosciences	13-Nov-17	Hayward, CA	Later Stage VC	Developer of innovative cancer immunotherapies created to target one or more therapeutic nodes and discover drugs that block tumors' ability to hijack the immune system.	107.00	Aisling Capital, BVF Partners, Celgene, Decheng Capital, Droia Oncology Ventures, EcoR1 Capital, GV, Hillhouse Capital Group, Invus Group, Leerink Partners, Taiho Pharmaceutical Company, The Column Group, Wellington Management, Foresite Capital Management

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
GI Windows	13-Nov-17	West Bridgewater, MA	Early Stage VC	Developer of novel technology designed to create anastomosis using a slender, linear device that can be loaded in the channel of a standard endoscope or a thin conduit, such as a catheter or needle, enabling healthcare providers to treat metabolic disorders on a same-day, outpatient basis, and with no surgical incisions.	9.50	Broadview Ventures, Undisclosed Investors
Personal Medication & Health Management	13-Nov-17	Novosibirsk, Russia	Early Stage VC	Developer of a telemedicine platform and aerosol inhalers equipped with temperature sensors and dose measurement sensors.	3.31	Foundation for Internet Development-Initiatives
Plant Advanced Technologies (ALPAT)	13-Nov-17	Vandoeuvre-lès-Nancy, France	PIPE	Provider of biotechnology research and development services intended to develop rare assets for cosmetic, pharmaceutical, and agrochemical markets.	0.59	Vetoquinol
SmartScripts	13-Nov-17	Washington, IA	Early Stage VC	Provider of a medication management technology that delivers prescriptions, vitamins, and supplements in a safe, convenient, and accurate system.	2.50	New Bohemian Innovation Collaborative, Next Level Ventures, Rural Vitality Fund
Steep Hill Labs	13-Nov-17	Berkeley, CA	Later Stage VC	Provider of medical cannabis testing and analytics services designed to measure the potency and safety of all cannabinoid infused products and medicines.	2.50	Gotham Green Partners, Slifka Asset Management
Verax Biomedical	13-Nov-17	Marlborough, MA	Later Stage VC	Developer of rapid tests for the detection of bacterial contaminants in blood cells and tissue.	11.44	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Wellthy	13-Nov-17	New York, NY	Seed Round	Provider of a healthcare management platform that offers care management services in complex health, chronic conditions, and aging related situations.	4.60	Aspiration Growth, HBS Alumni Angels New York, Hearst Communications, Jonathan Bush, Social Starts, Sweet Capital, Undisclosed Investors
Clario	14-Nov-17	Seattle, WA	Later Stage VC	Developer of workflow management software for hospitals, imaging centers, and private-practice radiology groups to improve radiologists' efficiency through the integration of multiple online tools.	0.74	Undisclosed Investors
Collective Medical	14-Nov-17	Draper, UT	Later Stage VC	Operator of a collaborative care management platform intended to improve patient outcomes by reducing the risk of emergency department visits and avoidable re-admissions for high-risk patients with complex needs.	47.50	Bessemer Venture Partners, EPIC Ventures, Kaiser Permanente Ventures, Kleiner Perkins Caufield & Byers, Maverick Ventures, Peterson Partners, Providence Ventures

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Color Genomics	14-Nov-17	Burlingame, CA	Later Stage VC	Developer of genetic testing kits created to screen for hereditary health issues.	89.44	Charles River Ventures, Emerson Collective, Fenox Venture Capital, Foresite Capital Management, General Catalyst Partners, Undisclosed Investors
ImmusanT	14-Nov-17	Cambridge, MA	Later Stage VC	Developer of a therapeutic vaccine designed to induce immune tolerance in celiac disease.	40.00	ARCH Venture Partners, Vatera Healthcare Partners
Locus Biosciences	14-Nov-17	Research Triangle Park, NC	Early Stage VC	Developer of sequence-specific precision antimicrobials for human infectious diseases.	19.00	Abstract Ventures, ARTIS Ventures, North Carolina Biotechnology Center, Tencent, Undisclosed Investors
Medigate	14-Nov-17	Tel Aviv, Israel	Seed Round	Developer of a medical device security platform dedicated to secure the use of connected devices, such as electronic medical records and device servers, on healthcare provider networks.	5.35	Blumberg Capital, YL Ventures
Monopar Therapeutics	14-Nov-17	Northbrook, IL	Angel	Developer of a novel monoclonal antibody compound that targets the urokinase plasminogen activator receptor, enabling its clients to develop life-altering orphan oncology therapeutics.	9.70	Undisclosed Investors
Operative Experience	14-Nov-17	North East, MD	Later Stage VC	Developer of simulation-based surgery training systems.	5.50	3B Scientific, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape



**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Relief Therapeutics (RLF)	14-Nov-17	Geneva, Switzerland	PIPE	Developer of peptides and proteins of natural and engineered origin to address unmet medical needs.	Undisclosed	Yves Sagot
Scipio Bioscience	14-Nov-17	Montrouge, France	Seed Round	Developer of a sample preparation product for single-cell studies in the form of benchtop kits to help in sequencing applications in clinical and basic research.	1.41	High-Tech Gründerfonds, Seventure Partners
Syapse	14-Nov-17	San Francisco, CA	Later Stage VC	Developer of software applications that integrate previously fragmented clinical, molecular, treatment, and health outcomes data and delivers it to physicians at the point of care, enabling oncologists to deliver personalized care.	30.00	Amgen Ventures, Ascension Ventures, GE Ventures, Healthbox, Medidata Solutions, Merck & Co., Roche Venture Fund, Safeguard Scientifics, Social Capital
Torque Therapeutics	14-Nov-17	Cambridge, MA	Early Stage VC	Developer of an online platform for providing immunotherapy services.	25.00	Flagship Pioneering, Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Tricida	14-Nov-17	South San Francisco, CA	Later Stage VC	Developer of non-absorbed oral drug therapies for patients with chronic kidney disease.	57.56	Cormorant Asset Management, Limulus Venture Partners, Longitude Capital, OrbiMed, Sibling Capital Ventures, Venrock, Vivo Capital, Wellington Management, Undisclosed Investors
Apton Biosystems	15-Nov-17	Pleasanton, CA	Later Stage VC	Developer of instruments focused on bio-marker identification and qualification for autoimmune, inflammatory, blood, and lymphatic diseases, as well as cancer.	8.00	Delphi Automotive, Israel Growth Partners, MediaTek Ventures, Samsung Catalyst, The Goldman Sachs Group
Catalia Health	15-Nov-17	San Francisco, CA	Seed Round	Developer of a cloud-based patient care management platform designed to address both sides of the healthcare equation, improving patients' health and extending the capabilities and efficiency of healthcare companies.	4.00	Abstract Ventures, Ion Pacific, Khosla Ventures, NewGen Capital, Tony Ling
Diamond Orthopedic	15-Nov-17	Charlotte, NC	Seed Round	Developer of a bone screw technology with lower insertional torque, an enhanced design that increases thread volume for better neighboring bone engagement, and higher pullout strength.	3.50	SigmaBleyzer

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Dynamic Biosensors	15-Nov-17	Martinsried, Germany	Early Stage VC	Provider of biochip software and devices designed for the analysis of molecular interactions.	5.87	Bayerische Beteiligungsgesellschaft
EFX Laboratories	15-Nov-17	Calgary, Canada	Angel	Provider of evidence-based cannabis formulations in dosage predictable, non-smokable formats to doctors and patients.	0.37	Undisclosed Investors
EnWave (ENW)	15-Nov-17	Vancouver, Canada	PIPE	Provider of an industrial-scale dehydration technology designed to be used in commercial applications in the food and pharmaceutical industries.	0.63	Undisclosed Investors
ExploraMed	15-Nov-17	Mountain View, CA	Later Stage VC	Provider of a medical technology incubator designed to leverage substantial financial and intellectual resources to accelerate the creation and establishment of new medical technologies, procedures, and companies.	8.76	Undisclosed Investors
Global Cannabis Applications (APP)	15-Nov-17	Vancouver, Canada	PIPE	Developer of an end-to-end data aggregation and user delivery system created to aggregate anecdotal and clinical trial data to pre-qualify candidates for clinical studies, increasing the speed and efficiency of data collection and the approval process for medical cannabis products.	1.18	Undisclosed Investors
Inozyme Pharma	15-Nov-17	Cambridge, MA	Early Stage VC	Developer of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism.	48.85	Longitude Capital, New Enterprise Associates, Novo Holdings, Sanofi-Genzyme Bioventures
Madorra	15-Nov-17	Portland, OR	Angel	Provider of a medical device designed to treat vaginal dryness for postmenopausal women.	Undisclosed	Undisclosed Investors
NeoPhore	15-Nov-17	Cambridge, United Kingdom	PE Growth/Expansion	Developer of novel small molecule therapies intended to treat cancer through stimulation of the immune system.	3.96	Sixth Element Capital

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Outpost Medicine	15-Nov-17	Lexington, MA	Early Stage VC	Developer of novel therapeutics for the treatment of urologic and gynecologic disorders.	61.00	Adams Street Partners, Frazier Healthcare Partners, Novo Holdings, Takeda Ventures, Vivo Capital
SportGait	15-Nov-17	Wilmington, NC	Angel	Provider of a concussion management technology using validated balance, gait, and neuropsychological testing in combination with sensor technology.	0.21	Undisclosed Investors
Turnpoint Medical Devices	15-Nov-17	Baskin Ridge, NJ	Angel	Developer of an infusion pump system for home infusion and cancer clinic markets.	3.38	Undisclosed Investors
Vesalius	15-Nov-17	Vancouver, Canada	Seed Round	Developer of a surgical implant designed to repair mitral regurgitation.	Undisclosed	Undisclosed Investors
Whistler Medical Marijuana	15-Nov-17	Whistler, Canada	Angel	Producer of organic medical marijuana.	1.45	Undisclosed Investors
X4 Pharmaceuticals	15-Nov-17	Cambridge, MA	Early Stage VC	Developer of novel therapeutics designed to improve immune cell trafficking and reverse immune suppression for treating cancer and immunodeficiency diseases.	27.00	Cormorant Asset Management, Undisclosed Investors
Xeltis	15-Nov-17	Zurich, Switzerland	Later Stage VC	Developer of bioabsorbable cardiovascular valves and vessels designed to allow endogenous tissue restoration.	52.80	Kurma Partners, Life Sciences Partners, VI Partners, Ysios Capital, Undisclosed Investors
iTherapyDocs	15-Nov-17	Albuquerque, NM	Angel	Developer of a documentation and billing software designed to simplify electronic health documentation while improving the revenue stream.	1.17	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Arterys	16-Nov-17	San Francisco, CA	Later Stage VC	Developer of a medical imaging technology designed to visualize and analyze blood flow inside the heart in 3D with automatic, interactive reporting.	30.06	Emergent Medical Partners, Fosun Capital Group, GE Ventures, New York Presbyterian Hospital, Northwell Ventures, ORI Capital, Temasek Holdings, Varian Medical Systems, DNA Capital, Undisclosed Investors
Diabetes Life Coach	16-Nov-17	Goshen, KY	Angel	Developer of a healthcare technology offering a coaching-motivational culture by providing measurable patient education and engagement and traceable cost improvements so patients can better manage their diabetes.	0.09	Undisclosed Investors
Elpis BioMed	16-Nov-17	Cambridge, United Kingdom	Seed Round	Provider of a cell reprogramming platform designed to produce pure, mature, and highly consistent batches of human cell types for research, toxicology, and drug development.	0.46	Darrin Disley, Jonathan Milner, Nikolaus Starzacher, Weslie Janeway

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Modulated Imaging	16-Nov-17	Irvine, CA	Later Stage VC	Developer of light-based technologies designed to help in quantitative evaluation of biological tissues.	2.86	Fresenius Medical Care Ventures, Grey Sky Venture Partners, Hamamatsu Photonics, Mitsubishi UFJ Capital
NAT Diagnostics	16-Nov-17	San Diego, CA	Angel	Developer of a molecular diagnostic platform designed to provide true point-of-care testing for infectious disease.	1.50	Undisclosed Investors
Physera	16-Nov-17	Palo Alto, CA	Early Stage VC	Developer of a SaaS-based health tracking mobile application designed to bring closed-loop machine learning to healthcare.	2.80	Expa Labs, iD Ventures America, Innovation Endeavors, Lux Capital, Slow Ventures
RDD Pharma	16-Nov-17	Tel Aviv, Israel	Early Stage VC	Developer of therapeutics for anorectal diseases and gastrointestinal disorders.	9.50	Capital Point, OrbiMed, Pharmascience
Vyrty	16-Nov-17	Redmond, WA	Angel	Developer of a health record management device.	0.50	Undisclosed Investors
WinSanTor	16-Nov-17	San Diego, CA	Angel	Developer of treatments for peripheral neuropathy.	0.78	Undisclosed Investors
Aston EyeTech	17-Nov-17	Birmingham, United Kingdom	Early Stage VC	Developer of decision support software designed to advance understanding of the development, use, preservation, and restoration of ocular function in humans by research on clinical and applied matters relevant to optometry and ophthalmology.	6.60	Mercia Technologies, Undisclosed Investors
CHD Bioscience	17-Nov-17	Fort Collins, CO	Angel	Developer of disinfectants to treat topical infectious diseases.	2.87	Undisclosed Investors
MicroTransponder	17-Nov-17	Austin, TX	Later Stage VC	Developer of therapies for the treatment of chronic pain, post-stroke upper limb mobility issues, and various neurological indications.	11.59	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Ncardia	17-Nov-17	Gosselies, Belgium	Early Stage VC	Developer of stem cell technology intended to support scientists operating in the hiPSC drug discovery and development space, including cardiovascular and neural safety and efficacy studies.	12.32	Epimède, Federal Holding and Investment Company, InnovationQuarter, SAMBRINVEST, Société Régionale d'Investissement de Wallonie, Vesalius Biocapital Partners
Sano Informed Prescribing	17-Nov-17	Franklin, TN	Angel	Provider of quantitative medication detection and therapy information services.	6.93	NueCura Partners, Undisclosed Investors
TeleClinic	18-Nov-17	Munich, Germany	Seed Round	Developer of a medical diagnoses and prescriptions platform designed to offer medical long-distance treatment.	2.35	Digital Health Ventures, Undisclosed Investors
Avalon GloboCare (AVCO)	20-Nov-17	Freehold, NJ	PIPE	Developer of a healthcare management platform designed to offer cell-based therapeutics and technologies.	5.15	Undisclosed Investors
ChroMedX (CHX)	20-Nov-17	Toronto, Canada	PIPE	Developer of medical devices for in-vitro diagnostics and point-of-care testing.	2.30	Undisclosed Investors
Illuma	20-Nov-17	Marietta, GA	Later Stage VC	Provider of an eye care coordination platform created to ensure diabetic patients get the eye care services they need.	0.90	Undisclosed Investors
Inflammatory Response Research	20-Nov-17	Santa Barbara, CA	Angel	Provider of drug development services for inflammatory disorders.	0.98	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Maven	20-Nov-17	New York, NY	Early Stage VC	Provider of a mobile application for women to book video appointments with healthcare practitioners.	10.87	14W, 8VC, BoxGroup, Colle Capital Partners, DGNL Ventures, Female Founders Fund, Great Oaks Venture Capital, Spring Mountain Capital, Undisclosed Investors
MedMinder	20-Nov-17	Needham, MA	Later Stage VC	Provider of an automated wireless pill dispensing system intended to simplify medication management and improve medication adherence.	0.61	Undisclosed Investors
Oviva	20-Nov-17	Zürich, Switzerland	Early Stage VC	Provider of a technology-enabled medical nutritional therapy platform for people with conditions such as obesity, diabetes, and food allergies.	12.00	Albion Capital, Eight Roads Ventures, F-Prime Capital Partners, Partech Ventures, Walking Ventures
Recro Pharma (REPH)	20-Nov-17	Malvern, PA	PIPE	Developer of non-opioid products, primarily the injectable meloxicam used for the treatment of acute pain, for hospitals and ambulatory care settings.	103.00	Athyrium Capital Management
AVM Biotechnology	21-Nov-17	Seattle, WA	Later Stage VC	Developer of stem cell technologies for regenerative medicine, oncology, and human biologics.	3.72	Undisclosed Investors



**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Candid Co	21-Nov-17	New York, NY	Early Stage VC	Provider of teeth alignment technology made of a smooth, comfortable, BPA-free plastic that won't irritate cheeks and gums.	15.00	Arena Ventures, Bessemer Venture Partners, e.ventures, Greycroft Partners, Undisclosed Investors
Neurolens	21-Nov-17	Costa Mesa, CA	Early Stage VC	Developer of corrective lenses intended to improve eye alignment and vision.	7.52	Undisclosed Investors
Preceptis Medical	21-Nov-17	Plymouth, MN	Later Stage VC	Developer of pediatric surgical technologies designed to offer a conscious sedation option for ear tube placement.	Undisclosed	Omphalos Venture Partners, Undisclosed Investors
Step Pharma	21-Nov-17	Paris, France	Early Stage VC	Developer of proprietary small molecule therapeutics for the treatment of auto-immune diseases.	17.01	Bpifrance, IdInvest Partners, Imagine Institute, Inserm Transfert Initiative, Kurma Partners, Pontifax Venture Capital, Sygnature Discovery
Svelte Medical Systems	21-Nov-17	New Providence, NJ	Later Stage VC	Developer of a drug-eluting coronary stent-on-a-wire integrated delivery system intended to treat coronary artery disease.	15.30	Undisclosed Investors
Turner Innovations	21-Nov-17	Orem, UT	Seed Round	Manufacturer of x-ray imaging systems intended to capture full fluoroscopy function and radiography image.	Undisclosed	Cavendish Impact Capital, Undisclosed Investors
1200 Pharma	22-Nov-17	Pasadena, CA	Early Stage VC	Developer of oncology drugs.	6.25	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Grail (Biotechnology)	22-Nov-17	Menlo Park, CA	Early Stage VC	Developer of a pan-cancer screening test designed to detect cancer early.	1211.66	Amazon.com, ARCH Venture Partners, Bristol-Myers Squibb, Celgene, Dentsu Ventures, Foresite Capital Management, JLABS, Johnson & Johnson Innovation - JJDC, Longwood Fund, McKesson Ventures, Merck, Tencent, Varian Medical Systems, Undisclosed Investors
Quantgene	22-Nov-17	Berkeley, CA	Angel	Developer of genomic diagnostics technologies that detect tumor mutations in standard patient blood samples at very low concentrations; effective for lung, breast, colorectal, pancreatic, liver, ovarian, and prostate cancer, as well as for melanoma, leukemia, non-hodgkin and hodgkin lymphoma.	6.13	Undisclosed Investors
Transonic Imaging	22-Nov-17	Los Angeles, CA	Angel	Developer of a breast scanning device designed to facilitate detection of malignant lesions.	4.04	Undisclosed Investors
Vigilant Diagnostics	22-Nov-17	Mound, MN	Seed Round	Developer of a technology created to improve the sensitivity and speed of infectious disease detection.	Undisclosed	BrilliMedical, Undisclosed Investors
Stemcell United (SCU)	23-Nov-17	Sydney, Australia	PIPE	Operator of a biotechnology company focused on the growth, reproduction, culture, and extraction of stem cells for medicinal, health, and beauty applications.	Undisclosed	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
The Biomed International	23-Nov-17	Kelowna, Canada	PIPE	Producer of medical marijuana and provider of scientific research and services related to the medical cannabis industry.	3.20	Alumina Partners
mPharma	23-Nov-17	Accra, Ghana	Early Stage VC	Provider of a pharmaceutical data analytics platform for pharmacies and their suppliers that manages prescription drug inventory and offers applications to prescribe and locate the medicines they need.	6.60	grey Sky Venture Partners, Hikma Ventures, LifeSciVC, Merck Ventures, Three Leaf Ventures, Undisclosed Investors
Eyecarrot Innovations (EYC)	24-Nov-17	Vancouver, Canada	PIPE	Developer of an eye testing platform created to integrate software, hardware, and data for effective eye testing and treatment.	1.25	Undisclosed Investors
LabGenius	24-Nov-17	London, United Kingdom	Seed Round	Developer of an autonomous AI-driven evolution engine for the discovery of high-value protein components.	3.66	Acequia Capital, Backed VC, Beast Ventures, Berggruen Holdings, Charles Songhurst, Kindred Capital, System.One, Thomas McInerney
Simedis	24-Nov-17	Saint Gallen, Switzerland	Early Stage VC	Developer of virtual reality simulators for medical education and training in all minimally invasive specialist areas.	4.99	Undisclosed Investors
B4CC	27-Nov-17	Gainesville, GA	Angel	Developer of a mobile application designed to continuously monitor and match options for cancer treatment, proactively search and provide personal ongoing search results, inform of latest treatments and clinical trials for the specific cancer, and easily share the precision-matched options with user's doctor.	0.56	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Biolinq	27-Nov-17	San Diego, CA	Early Stage VC	Provider of a skin-applied, minimally-invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid, enabling patients with diabetes to monitor their blood glucose without the pain and hassle of traditional systems.	10.00	Grey Sky Venture Partners, Hikma Ventures, LifeSciVC, Merck Ventures, Three Leaf Ventures, Undisclosed Investors
Camras Vision	27-Nov-17	Durham, NC	Angel	Developer of an ophthalmic medical device.	3.00	Undisclosed Investors
Doctolib	27-Nov-17	Paris, France	Later Stage VC	Developer of an application platform designed for patients to choose their doctor, make an appointment, and monitor their health.	41.06	Bpifrance, Eurazeo
Esculon	27-Nov-17	Omaha, NE	Seed Round	Developer of advanced surgical drainage systems intended to address expensive and frequent complications in patients undergoing open-heart or open-lung surgery by using a series of integrated sensors, algorithms, and small battery-powered controllers to monitor wound site drainage, ensure proper evacuation, and provide critical data for clinical decision support for the attending clinician.	2.93	Invest Nebraska, Ehrenberg Chesler, Undisclosed Investors
Fibralign	27-Nov-17	Union City, CA	Angel	Developer of advanced therapeutic biomedical devices using scaffolding technology that mimics human tissue structure and directly influences cell behavior as well as orientates collagen fibers to support the body's regenerative repair and maintenance process.	Undisclosed	angelMD
KalGene Pharmaceuticals	27-Nov-17	Kingston, Canada	Later Stage VC	Developer of precision medicine therapeutics created to slow the progression of Alzheimer's disease.	Undisclosed	Accel-Rx, Anges Québec, Anges Québec Capital, Lumira Capital, Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Medeor Therapeutics	27-Nov-17	San Mateo, CA	Early Stage VC	Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients.	57.00	6 Dimensions Capital, RA Capital Management, Sofinnova Ventures, Vivo Capital, WuXi Healthcare Ventures
Base Pair Biotechnologies	28-Nov-17	Pearland, TX	Early Stage VC	Provider of customized, consultative aptamer discovery and development services.	3.20	Base Pair Canada, BioTex med, Eventi Capital Partners, Undisclosed Investors
CinRx Pharma	28-Nov-17	Cincinnati, OH	Angel	Developer of therapeutics created to address substantial unmet medical needs across diverse disease indications.	10.00	Undisclosed Investors
Envisagenics	28-Nov-17	Huntington, NY	Seed Round	Developer of a bio-data analysis platform designed to extract biologically relevant RNA isoforms from raw RNA-seq data, enabling scientists to detect, quantify, and interpret ribonucleic acid sequencing for reducing drug-development risks.	2.50	Breakout Labs, Cosine, Dolby Family Ventures, Dynamk Capital, Empire State Development, SV Angel, Third Kind Venture Capital, Undisclosed Investors
Kineta	28-Nov-17	Seattle, WA	Later Stage VC	Developer of translational and immune modulating drugs to cure autoimmune diseases, viral diseases, and severe pain.	0.19	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Qool Therapeutics	28-Nov-17	Menlo Park, CA	Early Stage VC	Provider of a non-invasive system to induce therapeutic hypothermia for preservation of tissue following a heart attack, stroke, and traumatic brain injury.	8.00	BioPacificVentures, BrillMedical, FundRx, ShangBay Capital, SV Tech Ventures, TAMCAP, Western Technology Investment, Zhongji Holdings
Rx Savings	28-Nov-17	Overland Park, KS	PE Growth/Expansion	Provider of a web-based healthcare software designed for cost-saving services for purchasing prescription drugs.	18.44	McCarthy Capital, Undisclosed Investors
Sermonix Pharmaceuticals	28-Nov-17	Columbus, OH	Seed Round	Operator of a specialty pharmaceutical company offering healthcare products in women's health, menopause, and selective estrogen receptor modulators.	4.20	Richard DeSchutter, Undisclosed Investors
Vanc Pharmaceuticals (VANC)	28-Nov-17	Richmond, Canada	PIPE	Manufacturer and distributor of generic and over-the-counter pharmaceuticals.	0.57	Undisclosed Investors
XableCath	28-Nov-17	Arley, United Kingdom	Angel	Manufacturer of catheter-based devices created to treat peripheral and cardiovascular diseases.	1.17	Undisclosed Investors
Actinogen Medical (ACW)	29-Nov-17	Sydney, Australia	PIPE	Provider of biotechnology services focused on the development of novel treatments for Alzheimer's disease and other major age-related neurodegenerative disorders.	4.03	Undisclosed Investors
Apexian Pharmaceuticals	29-Nov-17	Indianapolis, IN	Later Stage VC	Operator of a clinical stage biotechnology platform designed to develop novel compounds to treat cancer.	4.80	Elevate Ventures
Arsanis (ASNS)	29-Nov-17	Waltham, MA	PIPE	Developer of monoclonal antibodies designed to prevent and treat serious infectious diseases.	20.00	New Enterprise Associates
BreStem Therapeutics	29-Nov-17	Raleigh, NC	Angel	Developer of a stem cell therapy for lung regeneration created to fight pulmonary fibrosis.	0.05	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Catalyst OrthoScience	29-Nov-17	Naples, FL	Early Stage VC	Developer of a next evolution shoulder replacement system created to make orthopedic surgery less invasive and more efficient.	3.60	Undisclosed Investors
Codiak	29-Nov-17	Cambridge, MA	Later Stage VC	Developer of a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need using its broad platform for the delivery of macromolecules to diverse cells and tissues.	76.50	Alaska Permanent Fund, Alexandria Venture Investments, ARCH Venture Partners, Casdin Capital, EcoR1 Capital, Fidelity Management & Research, Flagship Pioneering, Qatar Investment Authority, Sirona Biochem, Tavistock Group
Ixcela	29-Nov-17	Bedford, MA	Early Stage VC	Operator of a gut health and wellness firm focused on restoring internal fitness by a sophisticated test that identifies key small molecules associated with the gut microbiome that are out of balance, and an individualized therapy, enabling individuals to address health issues such as irritable bowel syndrome, acid reflux, and leaky gut.	1.82	Undisclosed Investors
Mavupharma	29-Nov-17	Kirkland, WA	Early Stage VC	Developer of non-nucleotide conditional modulators of the STING pathway that uses small molecules to indirectly and conditionally modulate the pathway by leveraging the innate immune system, providing orally bio-available treatment for patients with cancer and other infectious diseases.	20.00	Alpine BioVentures, Frazier Healthcare Partners

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
NanoCollect Biomedical	29-Nov-17	San Diego, CA	Early Stage VC	Developer of a microfluidic flow cytometry platform that enables biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, or basic research.	10.00	5 Prime Ventures, Agilent Technologies, Anzu Partners, FusionX Ventures, Illumina Ventures, Vertical Venture Partners
ProValens	29-Nov-17	Minneapolis, MN	Angel	Developer of a patient relations technology designed to manage and recommend resources, including educational content, Web and mobile apps, self-monitoring devices, and services, based on the individual needs of each patient.	0.25	Undisclosed Investors
Rhinomed (RNO)	29-Nov-17	Cremorne, Australia	PIPE	Developer and manufacturer of medical devices designed for snorers to breathe more easily through their nose and keep their mouth closed during sleep.	2.75	Undisclosed Investors
Terpenoid Therapeutics	29-Nov-17	Coralville, IA	Angel	Developer of anti-cancer therapeutic drugs.	1.34	Undisclosed Investors
US Med-Equip	29-Nov-17	Houston, TX	PE Growth/Expansion	Provider of rental movable medical equipment.	Undisclosed	Owner Resource Group
YmAbs	29-Nov-17	New York, NY	Early Stage VC	Developer of immunotherapy cancer treatments created to drive multiple product candidates in select solid tumor cancers.	80.00	HBM Healthcare Investments, Scopia Capital Management, Sofinnova Ventures, Undisclosed Investors
Aenitis Technologies	30-Nov-17	Paris, France	Early Stage VC	Developer of a medical technology for the separation, handling, and filtration of suspensions of particles or cells using acoustic forces generated by ultrasound.	4.69	Horizon 2019



**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Arzeda	30-Nov-17	Seattle, WA	Early Stage VC	Provider of an enzyme design technology that develops reaction-specific optimized enzymes by creating innovative cell factories that can transform or supplement current chemical production methods.	15.20	Bioeconomy Capital, Casdin Capital, OS Fund, Sustainable Conversion Ventures, Universal Materials Incubator, WRF Capital
CannTrust (TRST)	30-Nov-17	Vaughan, Canada	PE Growth/Expansion	Developer of cannabis-based medications.	20.00	Undisclosed Investors
Fractyl	30-Nov-17	Lexington, MA	Later Stage VC	Developer of a minimally invasive therapeutic procedure that remodels the lining of the upper part of the small intestine designed to address insulin resistance and restore metabolic health.	44.00	Bessemer Venture Partners, Crown Venture Fund, Deerfield Management, Emergent Medical Partners, General Catalyst Partners, GV, IDO Investments, Mithril Capital Management, True Ventures, Fahud Investment, Domain Associates

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
HeartFlow	30-Nov-17	Redwood City, CA	Later Stage VC	Developer of personalized medical technologies that provide healthcare professionals actionable knowledge about individual patients through non-invasive imaging technology coupled with computational fluid dynamics technology and big data software, providing them with treatments to treat patients with coronary artery disease.	90.00	Undisclosed Investors
ISeeYouCare	30-Nov-17	Evansville, IN	Angel	Provider of a patient-centric healthcare platform intended to manage, monitor, and digitize health records and make them accessible from multiple devices, anytime, anyplace.	2.52	Undisclosed Investors
Kiio	30-Nov-17	Madison, WI	Early Stage VC	Provider of a health engagement platform intended to automate the process of screening, assessment, triage, and exercise for low back pain, total joint replacement, and rehabilitation.	0.30	Undisclosed Investors
Living Matrix	30-Nov-17	VA	Angel	Developer of a cloud-based platform for patient information designed to streamline and automate the paper intake process.	4.42	Undisclosed Investors
Novonate	30-Nov-17	Palo Alto, CA	Early Stage VC	Developer of a medical device intended to protect and stabilize umbilical catheters in the neonatal intensive care unit.	0.62	California Institute for Quantitative Biosciences, Undisclosed Investors
ResTORbio	30-Nov-17	Boston, MA	Early Stage VC	Developer of medicines created to treat aging-related diseases and conditions caused by immunosenescence.	40.00	Fidelity Management & Research, Nest.Bio Ventures, OrbiMed, Quan Funds, Rock Springs Capital

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Semma Therapeutics	30-Nov-17	Cambridge, MA	Early Stage VC	Developer of transformative therapies designed to eliminate the use of insulin injections for Type-1 diabetes patients.	114.00	6 Dimensions Capital, ARCH Venture Partners, Cowen Group, Eight Roads Ventures, F-Prime Capital Partners, Medtronic, MPM Capital, Novartis, ORI Capital, Sinopharm Capital, T1D Fund, Wu Capital
ValiRx (VAL)	30-Nov-17	London, United Kingdom	PIPE	Developer of anti-cancer therapeutic products, drugs, treatments, and chemotherapies.	3.57	Undisclosed Investors

**Mergers and Acquisitions**

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Angle Technology Group (Andrew Newland)	Axela	Toronto, Canada	1-Nov-17	Provider of a portfolio of next generation, commercial stage, multiplex tools that provide enhanced analysis of proteins, DNA, and RNA that are specifically targeted at biomarker testing and infectious disease research and designed to facilitate the transition to personalized medicine.	4.82
Almac Group (Stephen Barr)	Bioclin Laboratories	Athlone, Ireland	1-Nov-17	Operator of a research laboratory providing diagnosis, treatment, analysis, and study of microbiology and pharmacokinetics.	Undisclosed
Ethismos Research (Anthony McKinney)	Euthymics Bioscience	Cambridge, MA	1-Nov-17	Developer of treatments for central nervous system disorders.	Undisclosed
Capio CFR (Thomas Kier)	MR Scanner Aarhus	Aarhus, Denmark	1-Nov-17	Provider of quality and efficient image diagnostic treatments.	Undisclosed
Körber (Henriette Viebig)	Systec & Services	Karlsruhe, Germany	1-Nov-17	Provider of consultancy and project management services in the pharmaceutical and biotechnology industries.	Undisclosed
Lee's Pharmaceutical Holdings (Benjamin Li)	Windtree Therapeutics (WINT)	Warrington, PA	1-Nov-17	Provider of biotechnological services offering a portfolio of products focused on improving the management of respiratory distress syndrome in premature infants with the goal of developing a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases.	10.00
PMC Group (US) (Raj Chakrabarti)	Yegna Manojavam Drugs and Chemicals	Choutuppal, India	1-Nov-17	Manufacturer of pharmaceuticals and intermediate chemicals.	Undisclosed
VAMED (Ernst Wastler)	Cleanpart Healthcare	Duisburg, Germany	2-Nov-17	Provider of medical device decontamination services.	Undisclosed
Clinigen Group (Shaun Chilton)	Quantum Pharmaceutical	Burnopfield, United Kingdom	2-Nov-17	Developer, manufacturer, and supplier of pharmaceuticals to the retail pharmacy, pharmaceutical wholesaler, and hospital markets.	198.54
Melinta Therapeutics (Paul Estrem)	Cempra Pharmaceuticals	Chapel Hill, NC	3-Nov-17	Developer of clinical-stage pharmaceutical products focused on medicines for curing bacterial infections.	Undisclosed
	Melinta Therapeutics (MLNT)	New Haven, CT	3-Nov-17	Developer of novel small-molecule antibiotics focused on the treatment of resistant infections, acute bacterial skin infections, methicillin-resistant staph infections, and gonorrhea.	Undisclosed
Innovest Global	Sanavida		6-Nov-17	Developer of a telehealth platform designed to provide round-the-clock access to physicians and pediatricians.	Undisclosed

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Mergers and Acquisitions**

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Ultragenyx Pharmaceutical (Emil Kakkis)	Dimension Therapeutics	Cambridge, MA	7-Nov-17	Developer of gene therapies for rare diseases starting with lead programs in hemophilia and building out a world-class product engine for adeno-associated virus therapeutics.	152.30
OncoResponse (Clifford Stocks)	Paganini Biopharma	Encino, CA	7-Nov-17	Provider of therapeutics for cancer treatment.	Undisclosed
Corix Bioscience (Michael Ogburn)	Pharmaceutical Development Company	Lesotho	7-Nov-17	Provider of research and development services based on cannabis plant, cannabis resin, and cannabinoid seeds.	3.13
Mesa Labs (Gary Owens)	BAG Health Care (Hygiene Monitoring business)	Lich, Germany	8-Nov-17	Developer of biological, cleaning, and chemical indicators, as well as a range of infection prevention products, used to assess the effectiveness of sterilization and disinfection processes.	Undisclosed
Cerenis Therapeutics	Lypro BioSciences	Berkeley, CA	8-Nov-17	Developer of a nano-based drug technology designed to increase the solubility and bio-availability of hydrophobic drugs and facilitate drug targeting to specific receptors.	Undisclosed
Haitong International Securities	Obagi Medical Products	Irvine, CA	10-Nov-17	Manufacturer and developer of skincare products to treat skin conditions such as premature skin aging, skin damage, hyper-pigmentation, acne, and sun damage.	190.00
MYnd Analytics (George Carpenter)	Arcadian TelePsychiatry	Philadelphia, PA	13-Nov-17	Operator of an online healthcare platform that uses machine learning, data analytics, and artificial intelligence to provide mental health services.	Undisclosed
Grupo Biotoscana (Mariano García-Valiño)	Laboratorio Dosa	Buenos Aires, Argentina	13-Nov-17	Manufacturer and seller of specialty pharmaceuticals.	29.90
Innovativ Media Group (Thomas Coleman)	Local Cannabis Dispensary	CA	13-Nov-17	Operator of an online cannabis dispensary store.	Undisclosed
Absorption Systems (Patrick Dentinger)	TGA Sciences	Medford, MA	13-Nov-17	Provider of biological research and development services.	Undisclosed
FujiFilm	Tokiwa-Bio	Tsukuba, Japan	13-Nov-17	Developer of a transgenic technology designed to develop gene therapy drugs for rare diseases.	1.51

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Mergers and Acquisitions**

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Invitae (Sean George)	CombiMatrix	Irvine, CA	14-Nov-17	Provider of pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders screening through DNA-based testing.	34.90
Monopar Therapeutics (Chandler Robinson)	Gem Pharmaceuticals	Birmingham, AL	14-Nov-17	Developer of anthracycline derivatives designed to eliminate the critical cardiotoxicity side effect of this powerful class of chemotherapeutics while maintaining their well-documented anti-cancer efficacy.	Undisclosed
Imagia (Frédéric Francis)	Cadens Imaging	Montreal, Canada	15-Nov-17	Developer of a medical imaging technology that combines 2D and 3D imaging, while keeping ergonomics simple, enabling doctors to capture improved diagnostic images.	Undisclosed
Banyan Software (David Berkal)	Medicat	Sandy Springs, GA	15-Nov-17	Developer of an on-premise patient health management platform designed to provide student healthcare services.	Undisclosed
CK Life Sciences International	Polynoma	San Diego, CA	16-Nov-17	Developer of an oncology-focused biotechnology vaccine for the treatment of melanoma.	Undisclosed
ILÚM Health Solutions (Paul Edwards)	Teqqa	Jackson, WY	16-Nov-17	Developer of mobile analytics software designed for infectious disease management.	Undisclosed
Standard Graphite (Chris Bogart)	Choom Holdings	Vernon, Canada	17-Nov-17	Manufacturer of cannabis-based medicine.	Undisclosed
Wize Pharma	Ophthalix	Petach Tikva, Israel	17-Nov-17	Provider of biopharmaceutical research services focused on building a pipeline of small-molecule drugs for the treatment of both niche and prevalent indications of cardiovascular and metabolic diseases.	Undisclosed
Optum	The Advisory Board Company	Washington, DC	17-Nov-17	Provider of technology and consulting services to healthcare organizations.	1300.00
Eris Lifesciences (Amit Bakshi)	Strides Shasun (domestic formulations business)	Bangalore, India	18-Nov-17	Provider of pharmaceutical formulation services.	77.02
Flexicare (Ghassem Poormand)	Medisize	Hillegom, Netherlands	20-Nov-17	Manufacturer of respiratory and anaesthesia products.	Undisclosed
Chengdu Kanghong Pharmaceutical	Ioptima	Tel Aviv, Israel	21-Nov-17	Manufacturer of minimally-invasive surgical ophthalmic devices created to offer laser technology for the treatment of glaucoma.	56.00

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Mergers and Acquisitions**

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Tieto	VisueCare	Kista, Sweden	21-Nov-17	Provider of cloud services intended to ensure a good quality of care and security for residents and relatives.	Undisclosed
Orig3n	Interleukin Genetics	Waltham, MA	22-Nov-17	Developer of genetic testing technology designed to adhere to the needs of chronic diseases and health-related conditions.	Undisclosed
TJR Coatings	DNA Logix Canada	Toronto, Canada	23-Nov-17	Marketer and distributor of diagnostic tests designed to detect the Zika virus.	0.24
Bunzl (Frank Van Zanten)	Interpath Services	Melbourne, Australia	23-Nov-17	Distributor of laboratory and healthcare related consumable products.	Undisclosed
Philips	Analytical Informatics	Baltimore, MD	24-Nov-17	Developer of a clinical software designed to optimize medical imaging equipment and personnel investments.	Undisclosed
	Sante Veritas Therapeutics	Vancouver, Canada	24-Nov-17	Operator of a medical cannabis cultivation company.	Undisclosed
	Pharmathen (Greece)	Pallini, Greece	30-Nov-17	Developer and marketer of prescription and over-the-counter drugs.	Undisclosed